Rose Hosts District Roundtable on Prescription Drug Prices

October 22, 2019 by Dan McCue

WASHINGTON – Rep. Max Rose hosted a roundtable for seniors in Brooklyn, N.Y. on Saturday to bring them up to speed on his proposal to lower prescription drug prices.

Rose met with members of AARP Bay Ridge Chapter 3630 to talk about his support of the Lower Drug Costs Now Act, which would lower prescription drug prices through direct negotiation, and now includes Rose’s More Help for Seniors Act of 2019, which would use savings from negotiations to lower Medicare Part D costs for low-income seniors.

The combined legislation:

·       Ends the blanket ban on Medicare negotiating directly with the drug companies, and creates powerful new tools to force drug companies to the table to agree to real price reductions, while ensuring seniors never lose access to the prescriptions they need;

·       Makes the lower drug prices negotiated by Medicare available to Americans with private insurance, not just Medicare beneficiaries;

·       Stops drug companies ripping off Americans while charging other countries less for the same drugs, limiting the maximum price for any negotiated drug to be in line with the average price in countries like ours, where drug companies charge less for the same drugs—and admit they still make a profit;

·       Creates a new, $2,000 out-of-pocket limit on prescription drug costs for Medicare beneficiaries, and reverses years of unfair price hikes above inflation across thousands of drugs in Medicare;

·       Lowers costs for low-income seniors by using savings to the Medicare Part D program to raise the income limits for eligibility under the Medicare Part D low-income subsidy program, which would help low-income seniors and individuals with disabilities afford needed medications by lowering copays and premiums for Medicare Part D.

·       Reinvests in innovation and the search for new cures and treatments, using some of the savings from lowering the unjustified drug prices that are bankrolling Big Pharma’s stock-buybacks to reinvest billions of dollars in the search for new breakthrough treatments and cures at the National Institutes of Health.

Rose, a former non-profit healthcare executive said,  “It’s time to change the law to let Medicare negotiate drug prices, and put those savings back in our seniors’ pockets. I appreciated having the opportunity to hear directly from those who have been hit hardest by skyrocketing prescription drug costs and look forward to getting this done.”

The non-partisan Congressional Budget Office found that drug negotiations alone from this transformative legislation will save taxpayers $345 billion in Medicare Part D spending over 2023-2029.

But the Pharmaceutical Research and Manufacturers of America, an industry association, says the sweeping Lower Drug Costs Now Act will do more harm than good.

In a statement following the introduction of the plan PhRMA president and CEO Stephen Ubl said the House plan “would end the current market-based system that has made the United States the global leader in developing innovative, lifesaving treatments and cures.”

He went on to say the Act would fundamentally restructure how patients access medicines and upend the successful Medicare Part D program that 40 million seniors rely on without any guarantee that savings would be used to lower costs at the pharmacy counter.

“We do not need to blow up the current system to make medicines more affordable,” Ubl said. “Instead, policymakers should pursue practical policy solutions such as sharing negotiated savings with patients at the pharmacy counter, lowering coinsurance in Medicare Part D, increasing transparency on patients’ costs, promoting value-based contracts, among other improvements to the system. These solutions are better alternatives to the far-reaching proposals in Speaker Pelosi’s plan.”

In The News

Health

Voting

Prescription Drugs

Democrats Seek Narrow Path to Rein in Cost of Medicines
Prescription Drugs
Democrats Seek Narrow Path to Rein in Cost of Medicines

WASHINGTON (AP) — President Joe Biden's call for authorizing Medicare to negotiate lower prescription drug prices has energized Democrats on a politically popular idea they've been pushing for nearly 20 years only to encounter frustration. But they still lack a clear path to enact legislation. That's... Read More

Pharmaceutical Executives Suggest Annual COVID-19 Vaccinations
Health
Pharmaceutical Executives Suggest Annual COVID-19 Vaccinations
April 19, 2021
by Tom Ramstack

Officials from the top U.S. pharmaceutical companies making the COVID-19 vaccine are saying vaccinated persons are likely to need booster shots within a year. In fact, they probably will need to get vaccinated yearly for the foreseeable future, similar to the annual flu vaccines. “A likely... Read More

Alarming Lapses in Inspection of Drugs Made in Foreign Countries
Prescription Drugs
Alarming Lapses in Inspection of Drugs Made in Foreign Countries
March 10, 2021
by Tom Ramstack

WASHINGTON -- A government report released Tuesday raised alarms about the quality of pharmaceuticals made in foreign countries but consumed by Americans. It said the purity of the drugs is questionable because of a lack of adequate inspections by the Food and Drug Administration of the... Read More

Lawmakers Lay Blame for Opioid Epidemic on Purdue Pharma
Prescription Drugs
Lawmakers Lay Blame for Opioid Epidemic on Purdue Pharma
December 18, 2020
by Tom Ramstack

WASHINGTON -- Members of Congress lashed into the Sackler family Thursday for its pharmaceutical company’s role in promoting a painkiller blamed for killing about 230,000 Americans. Lawmakers on the House Oversight and Reform Committee said the Sacklers and Purdue Pharma L.P. enriched themselves despite knowing about... Read More

Amid Hope for Pfizer Vaccine, States Grapple with Distribution
State News
Amid Hope for Pfizer Vaccine, States Grapple with Distribution

A COVID-19 vaccine from Pfizer Inc. may be on the horizon, but the cost of distributing vaccines across all 50 states and who will pay for that operation remains a huge stumbling block. What is clear is that much of the financial burden and logistical challenge of getting... Read More

Pfizer Says COVID-19 Vaccine Appears to be 90% Effective
Health
Pfizer Says COVID-19 Vaccine Appears to be 90% Effective
November 9, 2020
by Dan McCue

Stocks surged around the world Monday after Pfizer announced that early results from trials of its coronavirus vaccine suggest the shots may be 90% effective at preventing COVID-19. But President-elect Joe Biden quickly reminded Americans that the good news does not mean it's time to abandon... Read More

News From The Well
scroll top